Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple)

Año de publicación:

2020

PI:

Eloisa Riva

Revista / Publicación

Annals of Hematology

Cita:

Ann Hematol. 2020 May;99(5):1025-1030.

DOI:

DOI: 10.1007/s00277-020-03983-x
Descargar
Ver publicación

Otras publicaciones

  • 2024

The Latin American experience in POEMS syndrome

Descargar
Leer más
  • 2023

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Descargar
Leer más
  • 2023

Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting

Descargar
Leer más
  • 2023

Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group

Descargar
Leer más
  • 2022

Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America

Descargar
Leer más
  • 2022

Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study

Descargar
Leer más